An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir-grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study).
Fiche publication
Date publication
janvier 2023
Journal
Health science reports
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Bronowicki JP, Miailhes P, Hanslik B, Ouzan D, Larrey D, Riachi G, Truchi R, Jouannaud V, Pospait D, Abergel A, Causse X, Perot S, Skrzypski J, De Hautecloque A, Spampinato A, Mariot P, Sogni P,
Lien Pubmed
Résumé
The efficacy and safety profiles of elbasvir-grazoprevir (EBR/GZR) has been established in more than 10 clinical trials. However, the characteristics of patients treated in routine clinical practice may differ. The present study was therefore designed to assess the real-life effectiveness of EBR/GZR therapy in the general population and among subgroups with a high hepatitis C virus (HCV) prevalence in France.
Mots clés
elbasvir/grazoprevir association, hepatitis C virus, real‐world evidence study, sustained virologic response
Référence
Health Sci Rep. 2023 01;6(1):e619